Last reviewed · How we verify

Ranibizumab and Aflibercept

Instituto de Olhos de Goiania · FDA-approved active Small molecule

Ranibizumab and Aflibercept is a Anti-VEGF agent Small molecule drug developed by Instituto de Olhos de Goiania. It is currently FDA-approved for Neovascular (wet) age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion.

Ranibizumab and aflibercept are anti-VEGF agents that inhibit vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the retina.

Ranibizumab and aflibercept are anti-VEGF agents that inhibit vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the retina. Used for Neovascular (wet) age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion.

At a glance

Generic nameRanibizumab and Aflibercept
SponsorInstituto de Olhos de Goiania
Drug classAnti-VEGF agent
TargetVEGF-A (vascular endothelial growth factor-A)
ModalitySmall molecule
Therapeutic areaOphthalmology
PhaseFDA-approved

Mechanism of action

Both drugs bind to and neutralize VEGF-A, a key driver of pathological neovascularization and vascular permeability in retinal diseases. By blocking VEGF signaling, they reduce fluid accumulation, prevent new vessel formation, and stabilize or improve vision in conditions characterized by retinal vascular dysfunction. Ranibizumab is a humanized monoclonal antibody fragment, while aflibercept is a soluble VEGF receptor fusion protein.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ranibizumab and Aflibercept

What is Ranibizumab and Aflibercept?

Ranibizumab and Aflibercept is a Anti-VEGF agent drug developed by Instituto de Olhos de Goiania, indicated for Neovascular (wet) age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion.

How does Ranibizumab and Aflibercept work?

Ranibizumab and aflibercept are anti-VEGF agents that inhibit vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the retina.

What is Ranibizumab and Aflibercept used for?

Ranibizumab and Aflibercept is indicated for Neovascular (wet) age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion, Diabetic retinopathy.

Who makes Ranibizumab and Aflibercept?

Ranibizumab and Aflibercept is developed and marketed by Instituto de Olhos de Goiania (see full Instituto de Olhos de Goiania pipeline at /company/instituto-de-olhos-de-goiania).

What drug class is Ranibizumab and Aflibercept in?

Ranibizumab and Aflibercept belongs to the Anti-VEGF agent class. See all Anti-VEGF agent drugs at /class/anti-vegf-agent.

What development phase is Ranibizumab and Aflibercept in?

Ranibizumab and Aflibercept is FDA-approved (marketed).

What are the side effects of Ranibizumab and Aflibercept?

Common side effects of Ranibizumab and Aflibercept include Conjunctival hemorrhage, Eye pain or discomfort, Floaters, Increased intraocular pressure, Endophthalmitis (infection), Retinal detachment.

What does Ranibizumab and Aflibercept target?

Ranibizumab and Aflibercept targets VEGF-A (vascular endothelial growth factor-A) and is a Anti-VEGF agent.

Related